Two-year interim data from an ongoing phase 1/2 trial of the AAV-based gene therapy bidridistrogene xeboparvovec in six patients with limb-girdle muscular dystrophy show a safe profile and preliminary increased expression of the β-sarcoglycan protein.
- Jerry R. Mendell
- Eric R. Pozsgai
- Louise R. Rodino-Klapac
